title: Multifocal scalp abscess with subcutaneous fat necrosis and scarring alopecia as a complication of scalp mesotherapy.
abstract: Over the past several years, there has been a growing interest in the treatment method termed mesotherapy. Marketed for nonsurgical fat melting, skin rejuvenation, and hair regrowth, this technique has become increasingly popular and, in the public's view, it is considered to be a relatively benign intervention method. Mesotherapy was introduced over 50 years ago by M. Pistor, a French physician who utilized this technique initially as a novel analgesic therapeutic method for a variety of rheumatologic disorders. Since its introduction, the basic principal of locally injecting subcutaneous doses of varying chemicals has been expanded and is now utilized for the aforementioned cosmetic concerns. With its increased popularity, there has been an increase in the number of reported side effects resulting from mesotherapeutic intervention. We report multifocal scalp abscesses with subcutaneous fat necrosis as a direct result of mesotherapy; therefore, requiring extensive surgical repair.
authors.affiliation: Affiliated Dermatologists, Morristown, NJ, USA. razankadry@yahoo.com
authors.forename: Razan
authors.initials: R
authors.lastname: Kadry
authors.forename: Issam
authors.initials: I
authors.lastname: Hamadah
authors.forename: Abdullah
authors.initials: A
authors.lastname: Al-Issa
authors.forename: Lawrence
authors.initials: L
authors.lastname: Field
authors.forename: Fahad
authors.initials: F
authors.lastname: Alrabiah
mesh_terms: D000038:Abscess / Q000139:chemically induced / Q000473:pathology*; D000328:Adult; D000505:Alopecia / Q000139:chemically induced / Q000473:pathology*; D002921:Cicatrix / Q000139:chemically induced / Q000473:pathology; D045424:Complex Mixtures / Q000008:administration & dosage / Q000009:adverse effects*; D005218:Fat Necrosis / Q000139:chemically induced / Q000473:pathology*; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008419:Materia Medica / Q000008:administration & dosage / Q000009:adverse effects; D012536:Scalp Dermatoses / Q000139:chemically induced / Q000473:pathology*; D050151:Subcutaneous Fat / Q000473:pathology
chemical_list: D045424:Complex Mixtures; D008419:Materia Medica